AREV NanoTec joins BIO

VANCOUVER, BC – TheNewswire - February 23, 2021 - AREV NANOTEC BRANDS INC. (CSE:AREV) (OTC:AREVF) (“AREV Nanotec” or “AREV”), is pleased to announce that the Company has become a member of BIO, the Biotechnology Innovation Group, which is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other countries.

BIO is committed to speaking up for the millions of families around the globe who depend upon the success of advances in biotechnology. BIO is committed to driving a revolution that aims to cure patients, protect the climate, and nourish humanity. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. (  

Roscoe M. Moore, Jr., DVM, MPH, PhD, Former US Assistant Surgeon General (retired) and a board member of the Global Virus Network at the Institute of Human Virology, University of Maryland, who serves as the Senior Scientific Advisor for AREV stated, “Joining BIO is a logical and strategic step for AREV Nanotec, as the Company works to develop its medicinal extraction technologies for products like its recently announced SUS-TAINN™ branded Ready-to-Use Therapeutic Food (RUTF), its Enteral Formulas, and its phytomedicinal antiviral drug discovery platform.  AREV Nanotec is deliberately building its presence in the biotechnology space through directed appointments of experienced scientific advisors and corporate associations with potential biotech partners and respected trade associations like BIO.  AREV Nanotec continues to prove its commitment to an exciting pivot into the life sciences arena where its innovations will translate into substantial public benefit and shareholder value.”

AREV Nanotec CEO Mike Withrow stated, “We are excited to join BIO at this critical point for both the Company and global public health.  BIO embodies some of the core values of AREV Nanotec, including commitment to discovery, global health and wellness, and good business practices in the life science industry.  As AREV continues down its new path toward becoming a world leader in phytomedicinal research and development, human nutrition, and botanical extraction technologies, the Company will utilize its proprietary technologies to make a significant impact on the clinical challenges that BIO has prioritizes in this sector.”

For further information, contact Mike Withrow, 778-929-6536. For more information visit

On behalf of the Board,

Mike Withrow
CEO & Director

About AREV NanoTec Brands Inc.  
AREV NanoTec Brands Inc. (CSE: AREV) (OTC: AREVF) produces phytomedicinal extracts via its proprietary state-of-the-art extraction methodologies for the life science industry. These premium ingredients are utilized in SUS-TTAINN™, a READY TO USE THERAPEUTIC FOOD (RUTF’S) to impact global malnutrition on Savere / Accute Malnutrition (SAM) and the Enteral Formula markets. The AREV model is to advancel extraction technologies that provide opportunities for next generation phytomedicine.



Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements.  Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on   

Copyright (c) 2021 TheNewswire - All rights reserved.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.